Shilpa Medicare Ltd

Shilpa Medicare has announced its financial results for the quarter ending December 2024, showcasing improved operating profit and significant growth in both Profit Before Tax and Profit After Tax. The company also reported a higher inventory turnover ratio and a peak in Earnings per Share, while maintaining a low debt-equity ratio. However, cash and cash equivalents have decreased.

Shilpa Medicare's stock has declined significantly, continuing a downward trend that has seen it underperform its sector. The stock opened lower and reached an intraday low, trading below multiple moving averages. Over the past month, it has experienced a notable drop, contrasting with the broader market's stability.

Shilpa Medicare experienced a notable rebound on January 29, 2025, gaining 5.72% after three days of decline. The stock outperformed its sector and reached an intraday high, although it remains below several key moving averages. Its recent volatility contrasts with the broader market's performance.

Shilpa Medicare experienced a notable rebound on January 29, 2025, gaining 5.72% after three days of decline. The stock outperformed its sector and reached an intraday high, although it remains below several key moving averages. Its recent volatility contrasts with the broader market's performance.

Shilpa Medicare experienced a notable rebound on January 29, 2025, gaining 5.72% after three days of decline. The stock outperformed its sector and reached an intraday high, although it remains below several key moving averages. Its recent volatility contrasts with the broader market's performance.

Shilpa Medicare's stock has declined significantly, losing 5.41% on January 28, 2025, and continuing a downward trend over three days with a total drop of 16.99%. The stock is underperforming its sector and is trading below multiple moving averages, reflecting ongoing market challenges.

Shilpa Medicare's stock has faced a significant decline, losing 5.38% on January 27, 2025, marking its second consecutive day of losses. The stock opened lower and reached an intraday low, underperforming its sector while remaining above its 200-day moving average. Over the past month, it has declined 1.97%.

Shilpa Medicare has encountered significant challenges, with its stock declining 6.12% on January 13, 2025, and a total drop of 13.04% over four days. The stock is currently above the 200-day moving average but below several shorter-term averages, reflecting ongoing difficulties in the market.

Shilpa Medicare has recently undergone a revision in its score, reflecting ongoing challenges in the pharmaceuticals sector. The stock has been added to MarketsMOJO's list amid a notable decline in performance, underperforming its sector and experiencing a significant drop over the past month. Investors are closely monitoring its market position and key financial metrics.

Shilpa Medicare has been added to MarketsMOJO's list following a recent adjustment in its evaluation. The stock demonstrated a strong performance on December 18, 2024, with a significant gain, outperforming its sector. This positive trend reflects the company's resilience in the pharmaceuticals market amid broader market fluctuations.

Shilpa Medicare has experienced a revision in its score following recent market activity. Despite a notable decline in stock price and underperformance relative to the sector, the company remains a significant player in the pharmaceutical industry. It has been added to MarketsMOJO's list, suggesting ongoing interest from investors.

Shilpa Medicare has demonstrated a robust performance, gaining traction in the market with a notable increase in its stock evaluation. The company has been added to MarketsMOJO's list, reflecting a positive adjustment in its score. Investors are encouraged to maintain their positions as the stock continues to show growth potential.

Shilpa Medicare, a midcap pharmaceutical company, has seen a 6.12% rise in its stock price on November 21, 2024. With a 'Hold' rating from MarketsMOJO and outperforming the sector by 7.3%, the company's stock is currently trading close to its 52-week high and has shown consecutive gains in the last 2 days.

Shilpa Medicare, a midcap pharmaceutical company, has reported a strong financial performance in the quarter ending September 2024. The company has shown significant growth in its Profit Before Tax and Profit After Tax, with positive trends in key areas such as Operating Profit and Inventory Turnover Ratio. However, short term liquidity and dividend payout ratio have deteriorated. Investors are advised to hold their stocks, as recommended by MarketsMOJO.

Shilpa Medicare, a midcap pharmaceutical company, saw a 5.8% increase in its stock price on November 14, 2024, in line with the sector's performance. The stock has also shown a trend reversal, gaining after two consecutive days of falling. Its current trading is higher than its moving averages, indicating a positive trend. MarketsMOJO suggests a 'Hold' call for the stock.

On November 13, 2024, Shilpa Medicare's stock price declined by -5.46%, in line with the sector's performance. However, the stock showed some positive movement today, opening with a gain of 2.58%. Despite recent fluctuations, the stock is performing well in the long term, but may experience some volatility in the short term.

Shilpa Medicare, a midcap pharmaceutical company, has been upgraded to a 'Hold' by MarketsMOJO due to its strong financial performance in the last four quarters. The stock is currently in a bullish trend and institutional investors have shown confidence in its fundamentals. However, its long-term fundamental strength and expensive valuation should be taken into consideration.

Shilpa Medicare, a midcap pharmaceutical company, has seen a 5.8% increase in its stock price on November 11, 2024. Despite being given a 'Sell' call by MarketsMOJO, the company has outperformed its sector by 6.15% and has been on a consecutive gain streak for the last 5 days. Its stock is also trading higher than its moving averages, indicating a positive trend. Shilpa Medicare's strong performance showcases its potential in the pharmaceutical industry.